
This study aimed to evaluate the background and treatment course of patients with metastatic prostate cancer (PC). Disease progression on imaging without PSA elevation occurred not only during HSPC treatment and first‐line CRPC treatment but also during late‐line CRPC treatment. Patients with visceral metastases or those treated with upfront androgen receptor axis‐targeted or docetaxel may be more prone to such progression.
Like
Save
Share